This site uses cookies. By continuing to browse the site you agree to our policy on the use of cookies. Learn more here.
Decline
Accept
About Us - Company executives

Our mission

Improve healthcare by (1) measuring patient reported outcomes and the factors that influence them (2) developing therapeutic pathways for each individual.

Company executives

PhD, Founder and CEO
Alec Mian
PhD, Founder and CEO

Dr. Mian founded Curelator Inc. in 2013 based on the belief that one-size-fits-all medicine was failing the majority of humans who were not “average”. This short-coming is most acutely observed in chronic diseases with episodic attacks such as migraine, IBS, epilepsy, depression where medications are therapeutically effective in only a minority of patients.

The solution was to develop the first digital health platform using N=1 analytics to enable personalized measurement of therapeutic response and identification of disease modifying life-style factors. The Company’s first product is N1-Headache, which is indicated for migraine and is being used in multiple clinical studies.

Previously, Dr. Mian was CEO and a co-founder of Genmedica Therapeutics SL, a biotechnology company founded in 2005 in Barcelona, Spain to develop therapeutics for metabolic diseases such as type 2 diabetes. Under Dr. Mian’s leadership, Genmedica developed one of the few novel approaches for developing drugs that target disease pathogenesis rather than just symptoms. Using this approach Genmedica became one of Spain’s leading biotechnology startups, closing Spain’s largest life-science financing round in 2012. Genmedica’s compounds are currently in phase II clinical trials.

Before that, Dr. Mian was CEO and co-founder of Gamera Biosciences Corporation in Boston, USA which was founded in 1993 to develop high-speed, microfluidics technology for the drug discovery and genomics industries. The company was financed by local and international venture capital sources. In 1999 Gamera was sold to Tecan Ltd (SWX: TECN), a publicly-traded Swiss biomedical company.

Dr. Mian completed his Bachelors in biology at McGill University in Montreal, Canada. He completed his doctorate in genetics at University of Cambridge, UK, with Dr. Gabriel Dover; and Harvard Medical School, Boston, USA, with Dr. George Church. He is author or co-author of dozens patents and publications. Dr. Mian is a citizen of Germany and Canada.

Chief Operating Officer
David Verdura
Chief Operating Officer

David Verdura, is the Chief Operating Officer of Curelator, responsible for the operations and business development of the company. Most recently Mr. Verdura worked as an advisor to digital health startups and pharma companies designing digital strategies and solutions aimed at patients and health care professionals. He has focused on guiding his clients through their digital transformation journeys.

Previously, Mr. Verdura spent 12 years at Novartis Pharma. Up to 2016, he was Global Head of Digital Solutions. In this role, he was responsible for designing and executing the digital strategy for the Immunology and Dermatology business unit, as well as for developing digital solutions in conjunction with the global commercial and development teams. He was also Global Head of CRM Operations in 2010, responsible for designing and implementing a CRM strategy and support model globally, as well as overseeing the implementation of a new CRM system.

Prior to Novartis and until 2005 he worked at different consulting firms in the US, Mexico and Europe, such as KPMG, Deloitte and Cap Gemini, as well as being a freelance consultant in the area of management consulting and ERP across different industries.

In 2010 Mr. Verdura received executive education at IMD Business School, Lausanne, Switzerland and in 1994 received a B.S. in Industrial Engineering from Tecnológico de Monterrey (ITESM) in Mexico City.

PhD, FRSM, MICR, VP Clinical Development
Stephen Donoghue
PhD, FRSM, MICR, VP Clinical Development

Dr. Stephen Donoghue has more than 30 years clinical development experience as leader of global pharmaceutical projects. Therapeutic areas include neurological (migraine and other), cardiovascular, gastrointestinal and metabolic diseases.

He has worked as a drug development consultant to multiple companies over the past 9 years, including Genmedica Therapeutics. Previously he was VP Clinical Research Europe and head of the European development function with Elan Corporation, as well as global project leader, and played major roles in the development of products including: Tysabri (multiple sclerosis and Crohn’s disease), Neurobloc (torticollis), Zelepar (Parkinson’s disease), Zonegran (epilepsy) and Prialt (severe pain).

Prior to Elan Stephen was Senior Clinical Research Manager at Glaxo where he led an international team conducting phase 3 trials of sumatriptan for migraine - the first in class of the triptans which became a multi-billion dollar product. He was also clinical leader for the diabetes drug Troglitazone.

Stephen holds B.Sc. and Ph.D. degrees from Leeds University, UK and undertook post-doctoral academic research and teaching at Birmingham University and the Royal Free Hospital, London. Dr. Donoghue is a citizen of the UK.

Chief Information Security and Data Protection Officert
Vlad Gasic
Chief Information Security and Data Protection Officert

Vlad Gasic is responsible for the execution of Curelator’s Cybersecurity and Data Protection Program. In that role, he oversees implementation of program strategy and processes, in addition to managing risks, vulnerabilities and control practices. Mr. Gasic is also providing guidance on data protection and privacy matters as they relate to standards and regulations such as HIPAA and GDPR, among others.

Mr. Gasic is a seasoned professional with two decades of experience in IT and information security capacity. Prior to Curelator, he was employed by the Government of Ontario as the Lead Security Strategist for one of its key state-controlled agencies and was accountable for providing IT security vision, strategy, planning, implementation and management.

Before that, he worked as an Information Security Manager for SickKids Foundation in Toronto, Canada where he provided information security guidance to executive leadership by recommending security investments and best practices, and managing deployment of information security and risk management programs.

Mr. Gasic holds a professional designation of Certified Information Systems Security Officer (CISSO) and membership status in the International Association of Privacy Professionals (IAPP). He attended the University of McMaster (Canada) and is scheduled to graduate from the University of New South Wales in Australia with his Master’s in Cyber Security Operations in 2021.

VP Communications
Sandy Bodner
VP Communications

Sandy Bodner’s marketing and communications experience draws on more than 25 years of project work with a richly diverse clientele, including development-stage and established manufacturers of diagnostic tests and medical devices, as well as AIDS, human rights and and healthcare organizations.

As both an agency-based and independent consultant in the medical technology industry, she has worked in a wide variety of disease states (i.e., cancers of the bladder, breast, cervix, colon and prostate; Alzheimer’s disease, diabetes, and infectious disease), conducting interviews with clinical researchers, laboratory scientists and practicing clinicians, distilling complex often conflicting data, and devising strategic positioning platforms to help accelerate the “pathway to acceptance” of groundbreaking innovations designed to raise the standard of care.

Prior to establishing an independent consulting practice in 2007, Bodner spent a decade working for Lehman Millet, a medical marketing agency in Boston where she served as director of public and professional relations. Before that, she worked in high profile media relations in Los Angeles as a consultant for clients in book publishing and public affairs, including AIDS Healthcare Foundation, Arianna Huffington and Simon and Schuster; and in New York as director of media relations for the advertising agency Hill Holliday and publicity director of the mass market publishing division of Random House. In the human services category, her consulting practice won a Silver Anvil Award in 2013 from the Public Relations Society of America (PRSA) for a consumer marketing campaign conducted on behalf of Boston Community Capital, a 30 year old nonprofit dedicated to investing in underserved communities. Ms. Bodner is a citizen of the USA.

MD PhD, VP Clinical Statistics
Amparo Casanova
MD PhD, VP Clinical Statistics

Dr. Amparo Casanova has more than twenty years of experience in clinical research, biostatistics, clinical trials, and epidemiology, as a scientist and senior biostatistician.

Amparo has contributed to the design and publication of over a hundred research studies in multiple therapeutic areas, primarily cardiology (cardiovascular prevention, arrhythmias, acute coronary syndromes, interventional cardiology), neurology (stroke, neuroimaging), and endocrinology (diabetes). Her contributions to the advancement of clinical trials methodology, particularly in the area of sample size calculations for complex designs (cluster crossover trials), have been published and presented in international conferences.

Dr. Casanova obtained and MD (Faculty of Medicine) and PhD (Department of Statistics) from the University of Barcelona (Spain). She practiced medicine (occupational health) for seven years before joining the Department of Public Health in the University of Barcelona, to pursue her passion: a career in research. She has worked in the University of Barcelona (Spain), and the Universities of Toronto and McMaster (Canada). Amparo is a member of the Society for Clinical Trials, and of the Statistical Society of Canada.

PhD, Analytics Lead
Marina Vives-Mestres
PhD, Analytics Lead

Dr. Vives-Mestres has published 10 papers in indexed peer-reviewed journals in a wide range of areas (i.e., statistical quality control, economy, materials and headache) and has participated in more than 18 international conferences, some as an invited speaker.

She is also a visiting professor at the Universitat de Girona (Spain).

Marina Vives-Mestres studied Industrial Engineering at the Universitat Politècnica de Catalunya (UPC) in Barcelona (Spain) within the framework of a double diploma with the Institut des Sciences Appliquées de Lyon (France). She earned her Masters degree on Statistics and Operational Research (UPC and Universitat de Barcelona); became certified as a Six Sigma Black Belt; and completed a PhD on statistics applied to process monitoring at the Universitat de Girona.

She is the recipient of two awards from the European Network for Business and Industrial Engineering for the best student presentation (2015) and for the best presentation made by a non-academic (2018).

Lead Designer
Marc Albert
Lead Designer

Marc Albert is responsible for all Company brand and product-related design, including app and website development, clinical and instructional and educational materials.

He is a multidisciplinary designer with over 24 years experience working as a team leader or individual contributor. His career has encompassed fields as diverse as brand design and corporate identity, signage, packaging, editorial design, product design, museum design, and interactive digital media.

From 1999-2002 he was art director at Barcelona McCann & Erickson Worldwide, a world leader in advertising and communications for global companies. From 2002 to 2007, he was founder and CEO of Gruyere-bcn, a corporate communication studio with a team of eleven designers involved in a wide range of design and communication projects. At the same time, from 2002 to 2007 he was also Art Director at Angle Publishing House and La Evolución Barcelona (lighting company). Prior to joining Curelator in 2013, he performed freelance branding work for national and international corporate clients.

Mr. Albert’s education encompasses the world of corporate, product and software UI/UX design as well as marketing. He has a graduate degree in graphic design at EASDVic 1992-1997, Master in multimedia interface design at Elisava Barcelona 1999-2000, Human Computer Interaction in 2014 from London Nielsen Norman Group and Human-Computer Interaction for User Experience Design in 2019 from MIT (Massachusetts Institute of Technology); and a marketing degree from Esade Business School, Barcelona, in Spain, in the marketing management Program, 2008-2009.

Mr. Albert is a citizen of Catalunya, Spain.

PhD, VP Clinical Statistics (In Memoriam)
Francesc Peris
PhD, VP Clinical Statistics (In Memoriam)

Our dear colleague, Francesc Peris, the VP Analytics of Curelator Inc., passed away in August 2017 after a short illness. To us, he was a giant in univariate analysis.

Broadly speaking, he helped us develop a superior way to identify and measure the factors associated with debilitating episodic attacks in individuals (not simply populations, as is standard) with chronic disease. For N1-Headache, specifically, he helped develop and implement our N=1 data approach, which unscrambles the wide range of factors associated with increasing and decreasing (also new concept) the risk of migraine attack on an individual basis.

As a direct result of his work, the N1-Headache N-1 approach is still a bit ahead of its time. We don’t yet have competitors who are focusing on identifying - for each individual user - the things that make them feel worse or better, and enabling that person to act upon this information and then measure the results to determine whether adding or subtracting certain behaviors or foods might lessen the frequency or severity of their attacks.

Francesc was a dominant figure in statistical analysis in Spain, working on clinical trials for COPD, allergic rhinitis, schizophrenia, drug addiction, multiple sclerosis, alternatives to nephrostomy, and of course, migraine. He was 65 years old. We will miss him. Godspeed Francesc.

Peris F, Donoghue S, Torres F, Mian A, Wöber C.
Towards improved migraine management: Determining potential trigger factors in individual patients.
Cephalalgia 2017 Apr; 37(5): 452-463
Donoghue S, Mian A, Albert M, Boucher G, Peris F, Wöber C.
Identification of ‘protectors’ against migraine attacks using N1-Headache™.
Cephalagia. 2016;Vol. 36(1S) 1–185

Loading...